79 completed, 25 unknown, 17 terminated, 14 active not recruiting. 51 Phase 2, 36 Not applicable, 32 Phase 1, 22 Phase 3, 7 Early Phase 1.
Follow Carcinoma, Ductal: new trials by email Literature Review of Carcinoma, Ductal trials Research Report on Carcinoma, Ductal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 140 | 2026-09-09 | 2026-03-30 |
| CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) CD318-CAR-T cells - Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 38 | 2026-07-01 | 2025-09-03 |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer ctDNA-Guided Treatment Strategy - Breast Neoplasms, Carcinoma, Ductal, Breast | Not applicable | Recruiting | Natera, Inc. | 725 | 2026-05-08 | 2026-09-23 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Relacorilant, Nab-paclitaxel, Gemcitabine - Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | Recruiting | Corcept Therapeutics | 80 | 2026-01-27 | 2026-09-25 |
| Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer Acoustic Cluster Therapy, Modified FOLFIRINOX - Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Recruiting | EXACT Therapeutics AS | 25 | 2025-06-19 | 2026-10-13 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS Endoscopic ultrasound, EUS-Fine needle aspiration - Carcinoma, Pancreatic Ductal | Not yet recruiting | Peking Union Medical College Hospital | 900 | 2024-12-01 | 2024-04-09 | |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin - Carcinoma, Pancreatic Ductal | Phase 2 | Not yet recruiting | Ruijin Hospital | 20 | 2024-09-01 | 2024-08-27 |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. PF-07934040, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Active not recruiting | Pfizer | 64 | 2024-06-27 | 2026-10-13 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
| A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue Palliative radiotherapy - Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2023-07-24 | 2026-09-02 |
| LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg - Breast Cancer, DCIS | Phase 1 / Phase 2 | Completed | Integro Theranostics | 22 | 2023-07-14 | 2026-05-20 |
| Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies) - Carcinoma, Pancreatic Ductal, Prognosis | Not applicable | Active not recruiting | Institut Curie | 79 | 2022-12-12 | 2026-10-01 |
| Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer ultrasound combined with microbubbles - Invasive Breast Cancer, Cavitation | Unknown | Beijing Friendship Hospital | 30 | 2022-09-29 | 2023-12-06 | |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors RMC-6291 - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Active not recruiting | Revolution Medicines, Inc. | 222 | 2022-09-19 | 2026-05-15 |
Showing 20 of 160. Sign in to see all of them.
Carcinoma, Ductal, Breast (86) · Breast Neoplasms (78) · Carcinoma, Pancreatic Ductal (57) · Carcinoma, Lobular (28) · Pancreatic Neoplasms (28) · Carcinoma, Intraductal, Noninfiltrating (23) · Carcinoma, Non-Small-Cell Lung (16) · Colorectal Neoplasms (14) · Breast Carcinoma In Situ (12) · Inflammatory Breast Neoplasms (12) · Adenocarcinoma (9) · Neoplasm Metastasis (9) · Ovarian Neoplasms (9) · Colonic Neoplasms (8)
Neoplasms, Ductal, Lobular, and Medullary (160) · Neoplasms by Histologic Type (159) · Neoplasms, Glandular and Epithelial (159) · Carcinoma (156) · Neoplasms (154) · Neoplasms by Site (153) · Adenocarcinoma (151) · Skin Diseases (106) · Skin and Connective Tissue Diseases (106) · Breast Diseases (101) · Endocrine System Diseases (62) · Digestive System Diseases (61) · Digestive System Neoplasms (60) · Endocrine Gland Neoplasms (59)
Gemcitabine (15) · Paclitaxel (15) · 130-nm albumin-bound paclitaxel (14) · Carboplatin (12) · Albumin-Bound Paclitaxel (11) · Letrozole (8) · Radiotherapy (8) · Cyclophosphamide (7) · Cisplatin (6) · Doxorubicin (6) · Brachytherapy (5) · Chemotherapy, Adjuvant (5) · Fluorouracil (5) · Oxaliplatin (5) · Trastuzumab (5)
City of Hope Medical Center (4) · GBG Forschungs GmbH (4) · Pfizer (4) · RenJi Hospital (4) · Revolution Medicines, Inc. (4) · Alliance for Clinical Trials in Oncology (3) · Case Comprehensive Cancer Center (3) · Fudan University (3) · Intarcia Therapeutics (3) · Memorial Sloan Kettering Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Abramson Cancer Center at Penn Medicine (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Allist Pharmaceuticals, Inc. (2) · Angiodynamics, Inc. (2)
United States (94) · Canada (17) · China (16) · France (16) · Germany (13) · Italy (12) · Spain (12) · Netherlands (11) · United Kingdom (10) · Belgium (7) · Russia (7) · Australia (6) · South Korea (6) · Taiwan (6) · Puerto Rico (5)
Revolution Medicines, Inc. (3) · Bruce Haffty, MD (2) · Janice Lyons, MD (2) · Afshin Forouzannia, M.D. (1) · Alastair Thompson, MD (1) · Alphonse Taghian, MD, PhD (1) · Andreas Schneeweiss, MD, Prof. (1) · Angel Rodriguez, MD (1) · Ann Partridge, MD, MPH (1) · Anna Kirby (1) · Atif J Khan, MD (1) · Atif Khan, MD (1) · Baiyong Shen, PhD,MD (1)
PMID 34252375, PMID 30976202, PMID 33154826, PMID 34233640, PMID 37590355, PMID 38129778, PMID 40056080, PMID 11359672, PMID 12065558, PMID 16382061, PMID 16730270, PMID 17200148, PMID 17301074, PMID 17392300, PMID 17492927, PMID 17679725, PMID 17912636, PMID 17998546, PMID 18035213, PMID 18083065, PMID 18279765, PMID 18294778, PMID 18332471, PMID 18981464, PMID 19096768, PMID 19243946, PMID 19451433, PMID 19474112, PMID 19528136, PMID 19620489, PMID 19692688, PMID 19826126, PMID 20144231, PMID 20385495, PMID 20395062, PMID 20501712, PMID 21046229, PMID 21061074, PMID 21306953, PMID 21321298, PMID 21335417, PMID 21635709, PMID 21880792, PMID 21892704, PMID 21986093, PMID 22003243, PMID 22018631, PMID 22038501, PMID 22051734, PMID 22395644
P30CA033572 (3), P30CA072720 (3), 2014 (2), 2015 (2), 2016 (2), 2017 (2), 2025 (2), 2005 (1), 2009 (1), 2018 (1), 2019 (1), K07CA148888 (1), P30CA006973 (1), P30CA015704 (1), P30CA016056 (1)